Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and...

Area of Science:

• Endocrinology
• Medicinal Chemistry
• Oncology

Background:

• Aromatase is a critical enzyme in estrogen synthesis, making it a significant therapeutic target for estrogen receptor-positive breast cancer.
• Previous research indicated that COX-2 inhibitors, like nimesulide, could reduce aromatase activity independently of COX-2 inhibition.

Purpose of the Study:

• To develop and evaluate novel sulfonanilide compounds as selective aromatase modulators (SAMs).
• To explore the potential of these compounds in suppressing aromatase activity in breast cancer cells.
• To establish a pharmacophore model for guiding the design of potent aromatase inhibitors.

Main Methods:

• Combinatorial parallel synthesis was employed to generate a library of diverse sulfonanilide analogs.
• Pharmacological evaluation of synthesized compounds for aromatase suppression in SK-BR-3 breast cancer cells.
• Development of a ligand-based pharmacophore model using Catalyst HipHop algorithms.
• In vitro testing of lead compounds in aromatase-transfected MCF-7 cells.

Main Results:

• Novel sulfonanilides were successfully synthesized and demonstrated significant suppression of aromatase activity in SK-BR-3 cells.
• A pharmacophore model comprising an aromatic ring, two hydrogen bond acceptors, and one hydrophobic feature was identified for selective aromatase modulation.
• Lead compounds effectively reduced cellular aromatase activity in aromatase-transfected MCF-7 cells.

Conclusions:

• The synthesized sulfonanilides represent a promising class of compounds for targeting aromatase in breast cancer therapy.
• Both genomic and nongenomic mechanisms appear to contribute to the aromatase suppression effect of these novel compounds.
• The developed pharmacophore model can aid in the rational design of more potent and selective aromatase modulators.